QID 770170

Date Published: 2023-01-11

QID 770170: Red Hat OpenShift Container Platform 4.9. Security Update (RHSA-2022:9110)

Red Hat openshift container platform is Red Hat's cloud computing kubernetes application platform solution designed for on-premise or private cloud deployments.

Security Fix(es):
  • jenkins-plugin: arbitrary file write vulnerability in pipeline input step plugin (cve-2022-34177)

Affected Products:

  • Red Hat openshift container platform 4.9 for rhel 8 x86_64
  • Red Hat openshift container platform 4.9 for rhel 7 x86_64
  • Red Hat openshift container platform for power 4.9 for rhel 8 ppc64le
  • Red Hat openshift container platform for ibm z and linuxone 4.9 for rhel 8 s390x
  • Red Hat openshift container platform for arm 64 4.9 aarch64



Note: The preceding description block is extracted directly from the security advisory. Using automation, we have attempted to clean and format it as much as possible without introducing additional issues.

Successful exploitation of this vulnerability could lead to a security breach or could affect integrity, availability, and confidentiality.

  • CVSS V3 rated as High - 7.5 severity.
  • CVSS V2 rated as Medium - 5 severity.
    • Solution
    Refer to Red Hat security advisory RHSA-2022:9110 for updates and patch information.
    Vendor References

    CVEs related to QID 770170

    CVE-2022-34177 |
    Software Advisories
    Advisory ID Software Component Link
    RHSA-2022:9110 Red Hat Enterprise Linux CoreOS URL Logo access.redhat.com/errata/RHSA-2022:9110
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].